Korean Pharma Obtains Additional MFDS Approval for Pediatric Use of Constipation Treatment 'Crilol Liquid'

Korea Pharma announced on the 4th that its constipation treatment 'Crilol Liquid' has received approval from the Ministry of Food and Drug Safety (MFDS) as a pediatric treatment for children aged 6 months to 7 years.

Previously, Crilol Liquid was available for children aged 8 and above as well as adults. The company explained that with this new pediatric age approval, the prescription target has expanded, enabling increased sales.

Crilol Liquid is the first liquid-type constipation treatment jointly developed by Korea Pharma and IntroBioPharma. IntroBioPharma was responsible for development, while Korea Pharma licensed the technology for production and approval. The company aims to focus on additional new product development or approvals and diversify its portfolio.

Korea Pharma stated, "Existing powder-type acidic products must be dissolved in water before consumption, but Crilol Liquid, now approved for pediatric use, is an easy-to-consume liquid formulation," adding, "We plan to launch pediatric-specific packaging units to improve accessibility to constipation treatments for children."

They continued, "With pediatric sales added to the existing adult Crilol Liquid sales, annual revenue contribution is expected to exceed 3 billion KRW in five years," emphasizing, "We will enhance competitiveness in both central nervous system (CNS) and gastrointestinal products and lead the market."

This content was produced with the assistance of AI translation services.